| Literature DB >> 29625558 |
Takahiro Kanai1,2, Yuko Akioka3,4, Kenichiro Miura3, Masataka Hisano3, Junki Koike5, Yutaka Yamaguchi6, Motoshi Hattori3.
Abstract
BACKGROUND: C1q nephropathy (C1qN) was first described as glomerular disease characterized by predominant meangial C1q deposits in patients with proteinuria and no evidence of systemic lupus erythematosus. Several studies, however, revealed the clinical heterogeneity of C1qN, showing some cases with normal urinalysis. To confirm the existence of cases with predominant mesangial C1q deposits and negative or mild proteinuria and/or hematuria, we investigated renal graft biopsy specimens showing negative to mild proteinuria (less than or equal to 1+ by dip stick test) and/or hematuria.Entities:
Keywords: C1q deposits; C1q nephropathy; Clinicopathologic study; Protocol renal graft biopsy; Renal transplantation
Mesh:
Substances:
Year: 2018 PMID: 29625558 PMCID: PMC5889604 DOI: 10.1186/s12882-018-0874-9
Source DB: PubMed Journal: BMC Nephrol ISSN: 1471-2369 Impact factor: 2.388
Clinical and pathologic findings at the time when predominant mesangial C1q deposits were detected
| Case No. | Reason for RBx | Laboratory results | LM findings | IF findings | EM findings | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Up | OB | sCr [mg/dL] | IgG | IgM | IgA | C1q | C3 | Mes | Subend | Subep | ARB | |||
| 1 | Protocol | (−) | (−) | 0.7 | MGA | 2+ | 1+ | 1+ | 2+ | 1+ | (+) | (−) | (+) | – |
| 2 | Protocol | (+) | (−) | 0.6 | MGA | 2+ | 1+ | – | 2+ | 1+ | (+) | (−) | (−) | losartan potassium 100 mg/day |
| 3 | Protocol | (−) | (−) | 1.2 | MGA | 2+ | 1+ | – | 2+ | 1+ | (+) | (+) | (−) | – |
| 4 | Mild proteinuria | (+) | (−) | 0.7 | MGA | 2+ | 2+ | – | 2+ | 1+ | (+) | (−) | (−) | – |
| 5 | Protocol | (−) | (−) | 0.6 | MGA | 1+ | 1+ | – | 2+ | 1+ | (+) | (−) | (+) | losartan potassium 25 mg/day |
Abbreviation: No number, RBx renal biopsy, LM light microscopy, IF immunofluorescent, EM electron microscopy, Up urinary protein, OB occult blood, sCr serum creatinine, MGA minor glomerular abnormality, Mes mesangial deposits, subend subendothelial deposits, Subep subepithelial deposits
Clinical and pathologic findings 10 years later
| Case No. | Laboratory results | LM findings | IF findings | ARB | ||
|---|---|---|---|---|---|---|
| Up | OB | sCr [mg/dL] | ||||
| 1 | 1+ | – | 1.27 | MGA(8 y later) | NA | candesartan cilexetil 25 mg/day |
| 2 | 1+ | – | 1.39 | NA | NA | losartan potassium 100 mg/day |
| 3 | – | – | 1.78 | MGA (8 y later) | Negative for C1q, IgG, IgM, IgA and C3 | losartan potassium 25 mg/day |
| 4 | ± | – | 0.83 | NA | NA | valsartan 60 mg/day |
| 5 | – | – | 0.80 | NA | NA | losartan potassium 37.5 mg/day |
Abbreviation: No number, LM light microscopy, IF immunofluorescent, Up urinary protein, OB occult blood, sCr serum creatinine, MGA minor glomerular ab normality, NA not available, ARB angiotensin receptor blocker
Fig. 1Pathologic findings. a Minor glomerular abnormality. Periodic acid-Schiff stain. Original magnification × 600. b Immunofluorescence detection of C1q deposits in mesangial areas (2+ intensity). c Electron-dense deposits on mesangial and para-mesangial areas. d and e Minor glomerular abnormality. Periodic acid-Schiff stain. Original magnification × 200